EA017403B1 - Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов - Google Patents

Info

Publication number

EA017403B1

EA017403B1 EA200901067A EA200901067A EA017403B1 EA 017403 B1 EA017403 B1 EA 017403B1 EA 200901067 A EA200901067 A EA 200901067A EA 200901067 A EA200901067 A EA 200901067A EA 017403 B1 EA017403 B1 EA 017403B1

Authority

EA

Eurasian Patent Office

Prior art keywords

polypeptide

disease

vector

mammal

oligodendrocytes

Prior art date

2007-02-02

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004248 oligodendroglia Anatomy 0.000 title claims description 115
• 230000004069 differentiation Effects 0.000 title claims description 34
• 230000023105 myelination Effects 0.000 title claims description 33
• 230000001737 promoting effect Effects 0.000 title claims description 6
• 102100032795 Semaphorin-6A Human genes 0.000 title claims description 4
• 101710199479 Semaphorin-6A Proteins 0.000 title claims description 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 383
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 376
• 229920001184 polypeptide Polymers 0.000 claims abstract description 373
• 238000000034 method Methods 0.000 claims abstract description 192
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 101
• 201000010099 disease Diseases 0.000 claims abstract description 72
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 48
• 230000006378 damage Effects 0.000 claims abstract description 39
• 208000016192 Demyelinating disease Diseases 0.000 claims abstract description 18
• 206010012305 Demyelination Diseases 0.000 claims abstract description 18
• 206010067601 Dysmyelination Diseases 0.000 claims abstract description 11
• 210000004027 cell Anatomy 0.000 claims description 114
• 239000013598 vector Substances 0.000 claims description 73
• 235000001014 amino acid Nutrition 0.000 claims description 72
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 71
• 150000001413 amino acids Chemical class 0.000 claims description 68
• 230000014509 gene expression Effects 0.000 claims description 63
• 241000124008 Mammalia Species 0.000 claims description 55
• 101710100258 Plexin-A2 Proteins 0.000 claims description 49
• 239000000203 mixture Substances 0.000 claims description 49
• 102100034381 Plexin-A2 Human genes 0.000 claims description 46
• 239000012634 fragment Substances 0.000 claims description 37
• 229920000642 polymer Polymers 0.000 claims description 36
• 239000002202 Polyethylene glycol Substances 0.000 claims description 35
• 229920001223 polyethylene glycol Polymers 0.000 claims description 35
• 208000035475 disorder Diseases 0.000 claims description 28
• 108091033319 polynucleotide Proteins 0.000 claims description 28
• 102000040430 polynucleotide Human genes 0.000 claims description 28
• 241001465754 Metazoa Species 0.000 claims description 27
• 239000002157 polynucleotide Substances 0.000 claims description 27
• 210000002569 neuron Anatomy 0.000 claims description 22
• 230000035755 proliferation Effects 0.000 claims description 20
• 238000011282 treatment Methods 0.000 claims description 20
• 230000004083 survival effect Effects 0.000 claims description 19
• 230000004936 stimulating effect Effects 0.000 claims description 17
• 201000002491 encephalomyelitis Diseases 0.000 claims description 16
• 239000013604 expression vector Substances 0.000 claims description 14
• 230000003902 lesion Effects 0.000 claims description 14
• 208000011580 syndromic disease Diseases 0.000 claims description 14
• 210000000653 nervous system Anatomy 0.000 claims description 12
• 230000004770 neurodegeneration Effects 0.000 claims description 12
• 102000006386 Myelin Proteins Human genes 0.000 claims description 11
• 108010083674 Myelin Proteins Proteins 0.000 claims description 11
• 210000005012 myelin Anatomy 0.000 claims description 10
• 208000012902 Nervous system disease Diseases 0.000 claims description 9
• 239000013603 viral vector Substances 0.000 claims description 9
• 108060003951 Immunoglobulin Proteins 0.000 claims description 8
• 208000027418 Wounds and injury Diseases 0.000 claims description 8
• 230000001684 chronic effect Effects 0.000 claims description 8
• 230000034994 death Effects 0.000 claims description 8
• 102000018358 immunoglobulin Human genes 0.000 claims description 8
• 238000001802 infusion Methods 0.000 claims description 8
• 208000014674 injury Diseases 0.000 claims description 8
• 229920001515 polyalkylene glycol Polymers 0.000 claims description 8
• 241000701161 unidentified adenovirus Species 0.000 claims description 8
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 7
• 210000003169 central nervous system Anatomy 0.000 claims description 7
• 230000001404 mediated effect Effects 0.000 claims description 7
• 108010071390 Serum Albumin Proteins 0.000 claims description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
• 230000002490 cerebral effect Effects 0.000 claims description 6
• 238000002347 injection Methods 0.000 claims description 6
• 239000007924 injection Substances 0.000 claims description 6
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 6
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 6
• 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 5
• 208000001827 Ataxia with vitamin E deficiency Diseases 0.000 claims description 5
• 208000023105 Huntington disease Diseases 0.000 claims description 5
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 5
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 5
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 102000007562 Serum Albumin Human genes 0.000 claims description 5
• 206010047631 Vitamin E deficiency Diseases 0.000 claims description 5
• 208000029028 brain injury Diseases 0.000 claims description 5
• 238000002512 chemotherapy Methods 0.000 claims description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
• 230000007850 degeneration Effects 0.000 claims description 5
• 201000003264 familial isolated deficiency of vitamin E Diseases 0.000 claims description 5
• 238000000746 purification Methods 0.000 claims description 5
• 208000011403 Alexander disease Diseases 0.000 claims description 4
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 4
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 4
• 210000004899 c-terminal region Anatomy 0.000 claims description 4
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
• 235000018417 cysteine Nutrition 0.000 claims description 4
• 230000005855 radiation Effects 0.000 claims description 4
• 208000009174 transverse myelitis Diseases 0.000 claims description 4
• 241000701447 unidentified baculovirus Species 0.000 claims description 4
• 241001529453 unidentified herpesvirus Species 0.000 claims description 4
• 102100024321 Alkaline phosphatase, placental type Human genes 0.000 claims description 3
• 241000710929 Alphavirus Species 0.000 claims description 3
• 241000709661 Enterovirus Species 0.000 claims description 3
• 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
• 208000003435 Optic Neuritis Diseases 0.000 claims description 3
• 241000710778 Pestivirus Species 0.000 claims description 3
• 241000700584 Simplexvirus Species 0.000 claims description 3
• 241000700618 Vaccinia virus Species 0.000 claims description 3
• 201000011101 acute retrobulbar neuritis Diseases 0.000 claims description 3
• 235000020958 biotin Nutrition 0.000 claims description 3
• 239000011616 biotin Substances 0.000 claims description 3
• 229960002685 biotin Drugs 0.000 claims description 3
• 230000005764 inhibitory process Effects 0.000 claims description 3
• 238000007913 intrathecal administration Methods 0.000 claims description 3
• 230000001537 neural effect Effects 0.000 claims description 3
• 108010031345 placental alkaline phosphatase Proteins 0.000 claims description 3
• 208000022670 retrobulbar neuritis Diseases 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 2
• 238000007911 parenteral administration Methods 0.000 claims description 2
• 238000007920 subcutaneous administration Methods 0.000 claims description 2
• 230000001131 transforming effect Effects 0.000 claims description 2
• 102000001189 Cyclic Peptides Human genes 0.000 claims 5
• 108010069514 Cyclic Peptides Proteins 0.000 claims 5
• 241000616862 Belliella Species 0.000 claims 1
• 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
• 208000020339 Spinal injury Diseases 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 description 88
• 229940024606 amino acid Drugs 0.000 description 68
• 102000004169 proteins and genes Human genes 0.000 description 63
• 235000018102 proteins Nutrition 0.000 description 56
• 241000699670 Mus sp. Species 0.000 description 53
• 210000001519 tissue Anatomy 0.000 description 42
• 238000009739 binding Methods 0.000 description 33
• 230000027455 binding Effects 0.000 description 32
• 101710100264 Plexin-A4 Proteins 0.000 description 24
• 102100034385 Plexin-A4 Human genes 0.000 description 24
• 210000004556 brain Anatomy 0.000 description 24
• 230000004927 fusion Effects 0.000 description 23
• 238000009396 hybridization Methods 0.000 description 23
• 238000006243 chemical reaction Methods 0.000 description 22
• 241000699666 Mus <mouse, genus> Species 0.000 description 21
• 108020004414 DNA Proteins 0.000 description 19
• 230000015572 biosynthetic process Effects 0.000 description 19
• 239000003550 marker Substances 0.000 description 18
• 108010029485 Protein Isoforms Proteins 0.000 description 17
• 102000001708 Protein Isoforms Human genes 0.000 description 17
• 238000005755 formation reaction Methods 0.000 description 16
• 108010076504 Protein Sorting Signals Proteins 0.000 description 15
• 238000004458 analytical method Methods 0.000 description 14
• 230000001086 cytosolic effect Effects 0.000 description 14
• 108020001507 fusion proteins Proteins 0.000 description 14
• 102000037865 fusion proteins Human genes 0.000 description 14
• 239000000126 substance Substances 0.000 description 14
• 230000004048 modification Effects 0.000 description 13
• 238000012986 modification Methods 0.000 description 13
• 208000015122 neurodegenerative disease Diseases 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 12
• 238000012744 immunostaining Methods 0.000 description 12
• -1 radionuclides Proteins 0.000 description 12
• 125000003277 amino group Chemical group 0.000 description 11
• 238000001514 detection method Methods 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• 239000002773 nucleotide Substances 0.000 description 11
• 230000006320 pegylation Effects 0.000 description 11
• 230000028327 secretion Effects 0.000 description 11
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
• 241000700159 Rattus Species 0.000 description 10
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 10
• 125000004122 cyclic group Chemical group 0.000 description 10
• 239000003814 drug Substances 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 150000007523 nucleic acids Chemical group 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 102000014105 Semaphorin Human genes 0.000 description 9
• 108050003978 Semaphorin Proteins 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 238000004132 cross linking Methods 0.000 description 9
• 230000000694 effects Effects 0.000 description 9
• 230000035772 mutation Effects 0.000 description 9
• 102000039446 nucleic acids Human genes 0.000 description 9
• 108020004707 nucleic acids Proteins 0.000 description 9
• 210000002966 serum Anatomy 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 238000009007 Diagnostic Kit Methods 0.000 description 8
• 108091006905 Human Serum Albumin Proteins 0.000 description 8
• 102000008100 Human Serum Albumin Human genes 0.000 description 8
• 238000005917 acylation reaction Methods 0.000 description 8
• 239000013060 biological fluid Substances 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 239000003623 enhancer Substances 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 206010033799 Paralysis Diseases 0.000 description 7
• 210000003050 axon Anatomy 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 241000283690 Bos taurus Species 0.000 description 6
• 241000283086 Equidae Species 0.000 description 6
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 230000010933 acylation Effects 0.000 description 6
• 230000003376 axonal effect Effects 0.000 description 6
• 230000008499 blood brain barrier function Effects 0.000 description 6
• 210000001218 blood-brain barrier Anatomy 0.000 description 6
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 229920003023 plastic Polymers 0.000 description 6
• 239000004033 plastic Substances 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 235000002639 sodium chloride Nutrition 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 229920003169 water-soluble polymer Polymers 0.000 description 6
• 241000251468 Actinopterygii Species 0.000 description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
• 108091006146 Channels Proteins 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 239000004472 Lysine Substances 0.000 description 5
• 102100034382 Plexin-A1 Human genes 0.000 description 5
• 101710100257 Plexin-A1 Proteins 0.000 description 5
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 5
• 230000021736 acetylation Effects 0.000 description 5
• 238000006640 acetylation reaction Methods 0.000 description 5
• 230000009471 action Effects 0.000 description 5
• 238000005804 alkylation reaction Methods 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 238000004590 computer program Methods 0.000 description 5
• 230000002950 deficient Effects 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 235000019688 fish Nutrition 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 210000004885 white matter Anatomy 0.000 description 5
• QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 4
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 241000699800 Cricetinae Species 0.000 description 4
• 241000699802 Cricetulus griseus Species 0.000 description 4
• 241000938605 Crocodylia Species 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 208000028226 Krabbe disease Diseases 0.000 description 4
• 108091028043 Nucleic acid sequence Proteins 0.000 description 4
• 101710100263 Plexin A3 Proteins 0.000 description 4
• 102100034386 Plexin-A3 Human genes 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• 125000003172 aldehyde group Chemical group 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 239000007795 chemical reaction product Substances 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 150000001875 compounds Chemical class 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 230000003203 everyday effect Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 125000003827 glycol group Chemical group 0.000 description 4
• 239000007943 implant Substances 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 238000007917 intracranial administration Methods 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 230000035800 maturation Effects 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 210000001328 optic nerve Anatomy 0.000 description 4
• 230000035515 penetration Effects 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 4
• 230000006337 proteolytic cleavage Effects 0.000 description 4
• 238000005932 reductive alkylation reaction Methods 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 208000020431 spinal cord injury Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 108700024394 Exon Proteins 0.000 description 3
• 101001067187 Homo sapiens Plexin-A2 Proteins 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 238000005576 amination reaction Methods 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 210000001130 astrocyte Anatomy 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 239000010839 body fluid Substances 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 210000001638 cerebellum Anatomy 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 230000009693 chronic damage Effects 0.000 description 3
• 229940104302 cytosine Drugs 0.000 description 3
• 238000006471 dimerization reaction Methods 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• 238000010494 dissociation reaction Methods 0.000 description 3
• 230000005593 dissociations Effects 0.000 description 3
• AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 210000002950 fibroblast Anatomy 0.000 description 3
• 230000022244 formylation Effects 0.000 description 3
• 238000006170 formylation reaction Methods 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 238000004519 manufacturing process Methods 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 210000000274 microglia Anatomy 0.000 description 3
• 238000002703 mutagenesis Methods 0.000 description 3
• 231100000350 mutagenesis Toxicity 0.000 description 3
• 201000000050 myeloid neoplasm Diseases 0.000 description 3
• 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 230000003647 oxidation Effects 0.000 description 3
• 238000007254 oxidation reaction Methods 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 108010055896 polyornithine Proteins 0.000 description 3
• 229920002714 polyornithine Polymers 0.000 description 3
• 238000004393 prognosis Methods 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000002797 proteolythic effect Effects 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 239000004055 small Interfering RNA Substances 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 150000003573 thiols Chemical group 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 230000034512 ubiquitination Effects 0.000 description 3
• 238000010798 ubiquitination Methods 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• OWMCODAXNFNLCU-UHFFFAOYSA-N 2-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenol Chemical compound OC1=CC=CC=C1CNCCC1=CN=CN1 OWMCODAXNFNLCU-UHFFFAOYSA-N 0.000 description 2
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
• 230000005730 ADP ribosylation Effects 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• 241000700198 Cavia Species 0.000 description 2
• 241000252203 Clupea harengus Species 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• 239000004971 Cross linker Substances 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 108010067770 Endopeptidase K Proteins 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 2
• 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 108090000143 Mouse Proteins Proteins 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• 229930193140 Neomycin Natural products 0.000 description 2
• 206010029155 Nephropathy toxic Diseases 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241000282577 Pan troglodytes Species 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
• 241000277331 Salmonidae Species 0.000 description 2
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
• 108020004459 Small interfering RNA Proteins 0.000 description 2
• 108010090804 Streptavidin Proteins 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 102000007238 Transferrin Receptors Human genes 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 230000004520 agglutination Effects 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 210000000877 corpus callosum Anatomy 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 150000002118 epoxides Chemical class 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 210000000609 ganglia Anatomy 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 229960002989 glutamic acid Drugs 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 150000003278 haem Chemical class 0.000 description 2
• 235000019514 herring Nutrition 0.000 description 2
• 102000044428 human PLXNA2 Human genes 0.000 description 2
• 150000002430 hydrocarbons Chemical class 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
• 230000033444 hydroxylation Effects 0.000 description 2
• 238000005805 hydroxylation reaction Methods 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 238000003018 immunoassay Methods 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000026045 iodination Effects 0.000 description 2
• 238000006192 iodination reaction Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 239000002052 molecular layer Substances 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 210000000478 neocortex Anatomy 0.000 description 2
• 229960004927 neomycin Drugs 0.000 description 2
• 230000007694 nephrotoxicity Effects 0.000 description 2
• 231100000417 nephrotoxicity Toxicity 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 238000002135 phase contrast microscopy Methods 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 239000013600 plasmid vector Substances 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 230000013823 prenylation Effects 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• 229940043131 pyroglutamate Drugs 0.000 description 2
• 230000006340 racemization Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 239000013074 reference sample Substances 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 210000000582 semen Anatomy 0.000 description 2
• 238000007873 sieving Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 230000019635 sulfation Effects 0.000 description 2
• 238000005670 sulfation reaction Methods 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
• JPNBVWIRDQVGAC-UHFFFAOYSA-N (2-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=CC=C1[N+]([O-])=O JPNBVWIRDQVGAC-UHFFFAOYSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• BTBWSRPRAGXJJV-UHFFFAOYSA-N 2h-benzotriazole;carbonic acid Chemical class OC(O)=O.C1=CC=C2NN=NC2=C1 BTBWSRPRAGXJJV-UHFFFAOYSA-N 0.000 description 1
• QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 101100327149 Arabidopsis thaliana CCB1 gene Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 101100510326 Caenorhabditis elegans tpa-1 gene Proteins 0.000 description 1
• 241000282421 Canidae Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 108091028732 Concatemer Proteins 0.000 description 1
• 206010010254 Concussion Diseases 0.000 description 1
• 238000011537 Coomassie blue staining Methods 0.000 description 1
• 241000700626 Cowpox virus Species 0.000 description 1
• 235000000638 D-biotin Nutrition 0.000 description 1
• 239000011665 D-biotin Substances 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 101100371679 Dictyostelium discoideum ubpA gene Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 102100034240 ER membrane protein complex subunit 8 Human genes 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• 108010013369 Enteropeptidase Proteins 0.000 description 1
• 102100029727 Enteropeptidase Human genes 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 108010088842 Fibrinolysin Proteins 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 241000282818 Giraffidae Species 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
• 101000925848 Homo sapiens ER membrane protein complex subunit 8 Proteins 0.000 description 1
• 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
• 101001028659 Homo sapiens MORC family CW-type zinc finger protein 1 Proteins 0.000 description 1
• 101001067178 Homo sapiens Plexin-A4 Proteins 0.000 description 1
• 101001122597 Homo sapiens Ribonuclease P protein subunit p20 Proteins 0.000 description 1
• 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 208000033463 Ischaemic neuropathy Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
• 241001460053 Laides Species 0.000 description 1
• 208000037451 Leukoaraiosis Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 102100037200 MORC family CW-type zinc finger protein 1 Human genes 0.000 description 1
• 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101001115695 Mus musculus Myelin-oligodendrocyte glycoprotein Proteins 0.000 description 1
• 101001067176 Mus musculus Plexin-A4 Proteins 0.000 description 1
• 102000055324 Myelin Proteolipid Human genes 0.000 description 1
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 206010028570 Myelopathy Diseases 0.000 description 1
• 101150032381 NAT8 gene Proteins 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
• XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000002141 Pellagra Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 241000282405 Pongo abelii Species 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 239000005700 Putrescine Substances 0.000 description 1
• 208000019155 Radiation injury Diseases 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 108020005091 Replication Origin Proteins 0.000 description 1
• 208000037656 Respiratory Sounds Diseases 0.000 description 1
• 102100028674 Ribonuclease P protein subunit p20 Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• 102100022446 Transcription factor Sp4 Human genes 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 206010072731 White matter lesion Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 230000010516 arginylation Effects 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 108010006025 bovine growth hormone Proteins 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000012501 chromatography medium Substances 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000009514 concussion Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 229920000547 conjugated polymer Polymers 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000014510 cooky Nutrition 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 230000009483 enzymatic pathway Effects 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001033 ether group Chemical group 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 230000024924 glomerular filtration Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 239000010439 graphite Substances 0.000 description 1
• 229910002804 graphite Inorganic materials 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 102000047882 human INSR Human genes 0.000 description 1
• 102000051249 human Plxna4 Human genes 0.000 description 1
• 210000004408 hybridoma Anatomy 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• LFKYBJLFJOOKAE-UHFFFAOYSA-N imidazol-2-ylidenemethanone Chemical compound O=C=C1N=CC=N1 LFKYBJLFJOOKAE-UHFFFAOYSA-N 0.000 description 1
• 230000014726 immortalization of host cell Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000000951 immunodiffusion Effects 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000009434 installation Methods 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229950008325 levothyroxine Drugs 0.000 description 1
• 231100000861 limb weakness Toxicity 0.000 description 1
• 208000027905 limb weakness Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 208000018883 loss of balance Diseases 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 230000036963 noncompetitive effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000008055 phosphate buffer solution Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 210000005059 placental tissue Anatomy 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000007542 postnatal development Effects 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 235000008160 pyridoxine Nutrition 0.000 description 1
• 239000011677 pyridoxine Substances 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 206010037833 rales Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
• 238000005185 salting out Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 101150106357 slc32a1 gene Proteins 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 238000009331 sowing Methods 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 229940035722 triiodothyronine Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 108010087967 type I signal peptidase Proteins 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 108700026220 vif Genes Proteins 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 235000021119 whey protein Nutrition 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1